Tranexamic acid reduces blood loss of laminectomy and fusion for multilevel cervical myelopathy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPQ-16008539

Enrollment

Unknown

Registered

2016-05-26

Start date

2016-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multilevel cervical myelopathy

Interventions

2:Giving tranexamic acid before induction of anesthesia

1:Giving 0.9% NaCl before induction of anesthesia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All cervical multilevel compressive myelopathy from C3-C6 need laminectomy and fusion.

Exclusion criteria

Exclusion criteria: Chronic renal failure, cirrhosis of the liver, serious cardiac disease, allergy to TXA, a history of thromboembolic disease (deep vein thrombosis, ischemic heart disease, pulmonary embolism, transient ischemic attack, strokes, subarachnoid hemorrhage), bleeding disorders, hypercoagulation status, disseminated intravascular coagulation, pregnancy, cervical laminectomy and fusion not from C3 to C6.

Design outcomes

Primary

Measure	Time frame
blood lose;	—

Countries

China

Contacts

Public ContactCheng-Cheng Yu

Department of Spine Surgery, Honghui Hospital, Xi’an Jiaotong University Health Science Center

yccxiafeng@163.com+86 15229253802

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026